GLP-1 study debunks theory that medication slows Alzheimer's disease | wqad.com
wqad.com
A major Lancet study debunks the hopeful theory that GLP-1 diabetes drugs like semaglutide could slow Alzheimer's — revealing how medical optimism can outrun the evidence.
Hypothesis TestingTranslational Research GapEvidence-Based MedicineOptimism Bias
Theory Briefing
- A Lancet study found semaglutide, a popular diabetes medication, did not slow cognitive decline in adults with Alzheimer's disease.
- The result challenges a widely held hypothesis that GLP-1 receptor agonists might offer neuroprotective benefits beyond blood sugar control.
- The findings illustrate how promising mechanistic theories in medicine can fail to translate when rigorously tested in clinical trials.